GlassScriptPhysician profile
Harlan Curtis Rust
NPI 1952353195
$6,036.57
in general payments reported to CMS, 2019-2025
36 companies · $976 in 2025
The $976 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $278 · 2021: $311 · 2022: $749 · 2023: $1,537 · 2024: $1,149 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,326 · Education: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,325.97 |
| Education | $336.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $821.12 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $806.85 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $748.35 | 2021-2024 | |
| Amgen INC. | $314.71 | 2022-2025 | Tavneos, Aranesp, Parsabiv |
| Opko Pharmaceuticals, LLC | $313.60 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $285.29 | 2019-2024 | Veltassa |
| Travere Therapeutics, INC. | $259.31 | 2022-2025 | Filspari |
| Calliditas Therapeutics US INC. | $214.79 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $207.29 | 2019-2023 | Velphoro |
| Ardelyx, INC. | $187.76 | 2023-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $173.87 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $166.11 | 2022-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $160.36 | 2020-2025 | |
| Akebia Therapeutics INC | $128.20 | 2019-2025 | Auryxia, Vafseo |
| Takeda Pharmaceuticals U.S.A., INC. | $119.59 | 2020-2024 | Livtencity |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harlan Rust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.